Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001

Aug 18, 2020
Posted in: Investor updates

Home » Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001

Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001

Aug 18, 2020
Posted in: Investor updates

Imagion Biosystems Limited gives notice that, on 18 August 2020 the Company issued 21,633,200 fully paid ordinary shares (Shares) in the Company as the result of shareholders exercising their options in the Company.

Read the notice.

Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer

February 19, 2025

MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce

Corporate Update – IND for MagSense® HER2 Phase 2 Study Immediate Priority

November 14, 2024

Corporate Updates: $3M fundraising led by CPS Capital to be completed in early December Filing of IND for MagSense® HER2 Phase 2 Study Immediate Priority

Successful Placement of A$3M

October 10, 2024

Imagion Biosystems (ASX: IBX) (Company), is pleased to announce the Company has received $3 million of firm commitments through a highly successful capital raising. The

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.

Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001

Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001

Related Articles

Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer

Corporate Update – IND for MagSense® HER2 Phase 2 Study Immediate Priority

Successful Placement of A$3M

Transforming medical imaging for early disease detection

About Imagion Biosystems

Contact us

Join our email list